BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10697547)

  • 1. Irradiation induced clonogenic cell death of human malignant glioma cells does not require CD95/CD95L interactions.
    Streffer JR; Schuster M; Pohl U; Belka C; Dichgans J; Bamberg M; Weller M
    Anticancer Res; 1999; 19(6B):5265-9. PubMed ID: 10697547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells.
    Glaser T; Wagenknecht B; Groscurth P; Krammer PH; Weller M
    Oncogene; 1999 Sep; 18(36):5044-53. PubMed ID: 10490841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
    Winter S; Weller M
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1374-82. PubMed ID: 9732400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.
    Cerrato JA; Khan T; Koul D; Lang FF; Conrad CA; Yung WK; Liu TJ
    Int J Oncol; 2004 Feb; 24(2):409-17. PubMed ID: 14719118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
    Hermisson M; Weller M
    Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing.
    Wagenknecht B; Schulz JB; Gulbins E; Weller M
    Cell Death Differ; 1998 Oct; 5(10):894-900. PubMed ID: 10203695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
    Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
    Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C2-ceramide signaling in glioma cells: synergistic enhancement of CD95-mediated, caspase-dependent apoptosis.
    Wagenknecht B; Roth W; Gulbins E; Wolburg H; Weller M
    Cell Death Differ; 2001 Jun; 8(6):595-602. PubMed ID: 11536010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
    Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
    Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death.
    Steinbach JP; Wolburg H; Klumpp A; Weller M
    J Neurochem; 2005 Mar; 92(6):1340-9. PubMed ID: 15748153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.
    Naumann U; Kügler S; Wolburg H; Wick W; Rascher G; Schulz JB; Conseiller E; Bähr M; Weller M
    Cancer Res; 2001 Aug; 61(15):5833-42. PubMed ID: 11479223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma.
    Wagenknecht B; Glaser T; Naumann U; Kügler S; Isenmann S; Bähr M; Korneluk R; Liston P; Weller M
    Cell Death Differ; 1999 Apr; 6(4):370-6. PubMed ID: 10381630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells.
    Glaser T; Wagenknecht B; Weller M
    Oncogene; 2001 Aug; 20(35):4757-67. PubMed ID: 11521188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines.
    Schmidt F; Knobbe CB; Frank B; Wolburg H; Weller M
    Oncol Rep; 2008 Apr; 19(4):1061-6. PubMed ID: 18357397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
    Pohl U; Wagenknecht B; Naumann U; Weller M
    Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer.
    Rieger J; Ständer M; Löschmann PA; Heneka M; Dichgans J; Klockgether T; Weller M
    Oncogene; 1998 Nov; 17(18):2323-32. PubMed ID: 9811463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
    Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
    Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis.
    Steinbach JP; Eisenmann C; Klumpp A; Weller M
    Biochem Biophys Res Commun; 2004 Aug; 321(3):524-30. PubMed ID: 15358139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
    Wick W; Furnari FB; Naumann U; Cavenee WK; Weller M
    Oncogene; 1999 Jul; 18(27):3936-43. PubMed ID: 10435616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fas (APO-1/CD95) signaling pathway is intact in radioresistant human glioma cells.
    Yount GL; Levine KS; Kuriyama H; Haas-Kogan DA; Israel MA
    Cancer Res; 1999 Mar; 59(6):1362-5. PubMed ID: 10096571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.